Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 5/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076147 | 0.93 | CTSS (0.49) | CTSSCTSLCTSKFAAHCES1 | |
| SCHEMBL6076625 | 0.85 | FAAH (0.42) | CTSSCTSLFAAHCES1NCEH1 | |
| SCHEMBL14562995 | 0.85 | CTSS (0.48) | CTSSCTSLCTSKFAAHCES1 | |
| SCHEMBL14563109 | 0.85 | CTSS (0.48) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL14562977 | 0.82 | CTSS (0.46) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL5421398 | 0.82 | CTSS (0.46) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL14563000 | 0.81 | CTSS (0.50) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL5428498 | 0.81 | CTSS (0.45) | CTSSCTSLCTSKFAAHFKBP1A | |
| SCHEMBL14563089 | 0.81 | CTSS (0.45) | CTSSCTSLCTSKFAAHFKBP1A | |
| SCHEMBL6077373 | 0.81 | CTSS (0.41) | CTSSCTSLCTSKFAAHMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSL 11/4885CTSK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.